AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06190782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: systemic therapy alone
Description: 1.PD-1 inhibitor +/- Chemotherapy PD-1 inhibitor: all FDA approved PD-1 inhibitor producter is suitable~First line:~i. TP: paclitaxel 135-175mg/m2,d1+ DDP25mg/m2, d1-3 or 75mg/m2,d1;q21d (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternative) or ii. PF: DDP Second line (other platinum-based agents permitted as alternative such as carboplatin, nedaplatin, oxaliplatin, lobaplatin, etc.) i. Docetaxel or ii. Irinotecan or iii. Paclitaxel (albumin-bound paclitaxel or paclitaxel liposomes as alternative of paclitaxel permitted as alternatives)
Study NCT06006351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: manual therapy stretching exercises strengthening exercises electrotherapy applications
Study NCT06006351 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: manual therapy stretching exercises strengthening exercises electrotherapy applications
Study NCT06006351 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypervolt Device
Description: The painful area will be applied with a massage tool, and the frequency and mode of the tool will be adjusted in a way that does not disturb the patient.
Study NCT04821440 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Water displacement volumetry
Description: The examination will take place in several stages and by two operators. Initially, the patient will strip the limb concerned (leg or arm). Once the member is in the water column of the volumeter, a delimitation of the submerged area of the member will be carried out using a marking (black dermographic marker). Indeed, the level of acquisition in 3D is determined relative to the height of the water line marked on the skin with a black felt, this felt is usually used for venous mapping and is well tolerated The first operator will carry out two measurements one after the other with a change of water previously stabilized at room temperature.
Study NCT04821440 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Three dimension volumetry
Description: The 3D volumetric acquisition is done with the sensor (CE marking) attached to the touch pad and does not require invasive or cutaneous contact with the patient (minimum acquisition distance of 40 cm). The operator triggers the acquisition via a button in an application installed on the tablet and physically turns around the patient to carry out the acquisition of the affected member. At the end of the acquisition, the operator presses a stop button and chooses whether or not to calculate the volume using another button depending on the quality of the acquisition.
Study NCT06085742 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 60mg/m2 PO once a day (21 continuous days)
Study NCT06085742 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methotrexate
Description: 10mg/m2 PO BID on days 1, 8, and 15
Study NCT06085742 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Capecitabine
Description: 825mg/m2 PO BID on days 1-14
Study NCT03779685 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: Sevoflurane and morphine
Study NCT03779685 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Regional anesthesia
Description: Paravertebral block
Study NCT05725707 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Friendship Group
Description: Whether face-to-face or online delivery, each FG session followed the same broad format - (1) Group meditative exercise and reminder of group agreement (10 mins); (2) Check in with support group members and main session (50mins); (3) Summary of group discussion and homework activity planning (10mins); (4) Final group meditative exercise and closing of group (10mins). Session length was up to 80 minutes (see table 2) and each facilitator was provided with a manual describing each section as well as some hints and tips to promote discussion and engagement. While all FG's would follow this structure, group members would drive the content (particularly during Step 2).
Study NCT06427330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: 1. st dose is given after D+60：inotuzumab 0.3mg/m2~2. nd dose is given after 1 month：inotuzumab 0.6mg/m2
Study NCT05540977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil 5mg QN
Study NCT05540977 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Usual care
Study NCT06416137 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological tests
Description: Participants will be assessed with neuropsychological tests and will be collected information about their lifestyle, clinical history and sociodemographic status. Special attention will be paid to the presence of modifiable risk factors for dementia (i.e., low education, hearing impairment, traumatic brain injury, excessive alcohol consumption, obesity, smoking, hypertension, depression, physical inactivity, diabetes, and social isolation).
Study NCT05860322 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin is a water soluble non-digestible carbohydrate, and it is available in more than 36,000 species of plants. It is often used as dietary fiber and has obtained the Generally recognized as safe status (GRAS) by the Food and Drug Administration (FDA).
Study NCT05860322 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control
Study NCT04724317 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Steroid Group
Description: Ultrasound guided shoulder intra-articular steroid injection
Study NCT04724317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ozone Group
Description: Ultrasound guided shoulder intra-articular Ozone injection
Study NCT04724317 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRF Group
Description: Ultrasound guided shoulder intra-articular pulsed radiofrequency application
Study NCT06081309 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG-based personalized TMS
Description: Transcranial Magnetic Stimulation (TMS), in which treatment is personalized based on the participant's Electroencephalogram (EEG)
Study NCT05814523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganaxolone
Description: Ganaxolone will be administered as IV solution.
Study NCT05814523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as IV solution.
Study NCT05814523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: A non-anesthetic medication not previously used for treatment of SE within the current episode and will be administered at a dose sufficient for the termination of SE according to investigator judgment.
Study NCT05528120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC004 Capsules
Description: Oral administration after fasting/high-fat meal
Study NCT05528120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC004 Capsules
Description: Oral administration after high-fat/fasting meal
Study NCT05974371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: emotional context similarity
Description: On Day 1, all participants will encode AB neutral word pairs (e.g., Pencil - Car) shown with positive, negative, or neutral images. On Day 2, all participants will encode AC neutral words pairs (e.g., Pencil - Book) alongside images of either the same or different valence. The emotional similarity of AB (Day 1) and AC (Day 2) image contexts (i.e., the independent variable) will consist of the following conditions: positive-positive, positive-negative, negative-negative, negative-positive, neutral-neutral, neutral-positive, and neutral-negative.
Study NCT05828433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Epley-Canalith Repositioning
Description: Epley-Canalith Repositioning The intervention was given for approximately 15min, for 2 times in a week, for 4 weeks.
Study NCT05828433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation Therapy
Description: Vestibular Rehabilitation Therapy Habituation exercises: The patients were asked to repeat the exercises 5 -10 times for 5 to 10 min, for 2 days in a week, for 4 weeks.~Gaze stability exercises and balance training: The exercises were performed in 3 sets or 5 repetitions, for 2 days in a week, for 4 weeks.
Study NCT06203691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementation with Nirvana Super Pro Liquid Supplements
Description: Intervention will measure strength pre \& post operatively. Intervention group will receive liquid supplements (3oz daily shots) pre (Prepare) and Post (Recover) operatively.
Study NCT06203691 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Non-Supplementation Group
Description: Intervention will measure strength pre \& post operatively. Intervention group will not receive liquid supplements.
Study NCT06104059 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nociception level index (NOL™)
Description: If a NOL value >25 persists for >1 minute a bolus of iv fentanyl 0.5mcg/kg will be given and reassessment of the NOL value will continue every 5 minutes. If NOL index value: 10-25 is not reached within 10 minutes, fentanyl 0.5mcg/kg iv is re-administered.
Study NCT06104059 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Bolus doses of iv fentanyl 0.5 mcg/kg will be administered based on the judgment of the anesthesiologist in charge.
Study NCT05724797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRS-033
Description: A single dose of NRS-033 will be administered
Study NCT05724797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of matching placebo will be administered
Study NCT06098521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CONSENT
Description: The CONSENT program is a risk-, need- and responsivity (RNR) based CBT program primarily focused on reducing risk of sexual reoffending, that consists of 18-26 one-to-one sessions in correctional settings.
Study NCT04710797 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Completion staging surgery including systematic pelvic and para-aortic lymphadenectomy
Description: * open or minimally invasive surgical approach~* cytologic examinations~* All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied~* BSO and hysterectomy~* For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered~* Omentectomy~* Para-aortic lymph node dissection should be performed by stripping the nodal tissue from the vena cava and the aorta bilaterally to at least the level of the inferior mesenteric artery and preferably to the level of the renal vessels~* The preferred method of dissecting pelvic lymph nodes is bilateral removal of lymph nodes overlying and anterolateral to the common iliac vessel, overlying and medial to the external iliac vessel, overlying and medial to the hypogastric vessels, and from the obturator fossa at a minimum anterior to the obturator nerve
Study NCT04710797 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comprehensive staging surgery with no Lymphadenectomy
Description: * open or minimally invasive surgical approach~* cytologic examinations~* All peritoneal surfaces should be visualized, and any peritoneal suspicious for metastasis should be selectively excised or biopsied~* BSO and hysterectomy~* For selected patients desiring to preserve fertility, USO or BSO with uterine preservation may be considered~* Omentectomy~* In open approach surgery, exploring the pelvic and Para-aortic lymph node with hand. In minimally invasive surgery, the peritoneal above the pelvic and Para-aortic lymph node area should be open and visualized.Biopsy and frozen section of the suspicious lymph nodes
Study NCT04256005 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will complete one of two exercise conditions (50% Delta GET or 105% VO2peak).
Study NCT06412068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined anti-PD-1 and R-CHOP
Description: Sintilimab,200mg, d1, intravenous drip; Rituximab,375mg／㎡, d1,intravenous drip; Cyclophosphamide,750mg／㎡,d2,intravenous drip; Doxorubicin,50mg／㎡ （or Liposome doxorubicin ，40 mg／㎡）,d2,intravenous drip; Vincristine,1.4mg／㎡, d2（Maximum dose 2mg),intravenous drip; Prednisone, 60mg/ m2 , d1-d5,oral administration.
Study NCT05948436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clamping the uterine artery bilaterally during Cesarean section
Description: We clamped the uterine artery by Darmklemmen clamp, which grasps the tissue delicately without damage, after the delivery of the baby before the delivery of placenta. The clamp is released after the suturing of Munro-Kerr incision is finished, before bleeding control. The duration of clamping time is recorded.
Study NCT05423301 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Respiratory care consists of manual and instrumental bronchial clearance techniques: Expiratory Flow Enhancement (EFE), suctioning, manual cough assist techniques, instrumental clearance techniques (suctioning and Cough Assist) and swallowing disorder management.)
Study NCT05423301 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will receive early respiratory care and rehabilitation by nurses, nurses' aides and doctors until D7. Respiratory care includes aerosol therapy, oral and pharyngeal clearance with aspirations, verbal coughing and sputum removal, and possibly bronchial fibroscopy for clearance if necessary. Early rehabilitation consists of alternating postures in bed, passive chair positioning (patient lift), or active positioning via a bed rail and standing.
Study NCT05584774 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PELDAN
Description: percutaneous endoscopic lumbar dissectomy and annuloplasty and nucleoplasty
Study NCT05584774 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PELDAN
Description: percutaneous endoscopic lumbar dissectomy and annuloplasty and nucleoplasty
Study NCT05213507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aerosol inhaled Amikacin Sulfate Injection
Description: 0.4g Amikacin sulfate injection + 5ml saline, aerosol inhalation, b.i.d., 7-10 days per month, for 3 months.
Study NCT05213507 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional therapy
Description: According to the personal characteristics of subjects and guidance of The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2021, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled corticosteroids and long-term oxygen therapy.
Study NCT05213507 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional therapy
Description: According to the personal characteristics of subjects and guidance of The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2021, the doctor in charge prescribes appropriate medication, including but not limited to bronchodilators, inhaled corticosteroids and long-term oxygen therapy.
Study NCT04603079 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention for COVID-19 preventive protocols
Description: The intervention will comprise (A) digital communication of written material and (B) monthly online training and discussion through skype and zoom, to allow for physical demonstrations, Q\&A and sharing of challenges. The five specific areas covered in the intervention for COVID-19 preventive protocols will include: (1) PPE fitting, (2) PPE removal, (3) hand hygiene, (4) cleaning, disinfection and sterilization, and (5) nurse uniform sterilization.
Study NCT04584372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-nitrate intervention
Description: The 2×70 mL of nitrate-rich (i.e., 'high nitrate') beetroot juice contains 12.9 mmol nitrate (NO3-).
Study NCT04584372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low-nitrate intervention
Description: The 2×70 mL of nitrate-depleted (i.e., 'low nitrate') beetroot juice contains 0.04 mmol (or less) nitrate.
Study NCT05364047 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Low-dose of LVRNA009
Description: 25μg/person
Study NCT05364047 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Middle-dose of LVRNA009
Description: 50μg/person
Study NCT05364047 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: High-dose of LVRNA009
Description: 100μg/person
Study NCT05162885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Socket Preservation technique
Description: Implant placement after Socket preservation Technique with sodium alderonate versus sticky bone in salama\&salama Class 3 labial wall defect
Study NCT04945161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ON101 Cream
Description: Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
Study NCT04945161 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05997485 — intervention group
Intervention type: DRUG
Intervention: Nirmatrelvir/Ritonavir
Description: Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.
Study NCT02684383 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN3∆30
Description: 10\^3 plaque-forming units (PFUs); administered by subcutaneous injection in the deltoid region of the upper arm
Study NCT02684383 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection in the deltoid region of the upper arm
Study NCT05131997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-221
Description: PO, Once daily(QD), 8 weeks
Study NCT05131997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD-221A
Description: PO, Once daily(QD), 8 weeks
Study NCT05131997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-221B
Description: PO, Once daily(QD), 8 weeks
Study NCT05131997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AD-221C
Description: PO, Once daily(QD), 8 weeks
Study NCT06539819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Posterior Box Isolation and Rotor Modulation Ablation group (R&B group)
Description: the intervention is conducting electrical posterior box isolation plus rotor modulation ablation
Study NCT06539819 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical Posterior Box Isolation group (BO group)
Description: the intervention is conducting electrical posterior box isolation alone
Study NCT04768764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Middle Adductor Canal Block
Description: Middle adductor canal block will be applied post-operatively with guidance of USG.~Drug:Bupivacaine 0.25% Injectable Solution
Study NCT04768764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Femoral Nerve Block.
Description: Femoral nerve block will be applied post-operatively with guidance of USG. Drug:Bupivacaine 0.25% Injectable Solution
Study NCT04768764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: 10 ml %0,5 Bupivacaine will be diluted with 10 ml saline solution. Bupivacaine 0.25% Injectable Solution
Study NCT04768764 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Patients will be placed in the lateral decubitus position.Subarachnoid space will be entered through the most suitable intervertebral space.Bupivacaine 0.5% Heavy will be given in the appropriate dose.
Study NCT05285332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical treatment 1
Description: Mastectomy OR Breast conserving surgery
Study NCT05285332 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical treatment 2
Description: Resection of metastasis
Study NCT05285332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: Endocrine therapy or chemotherapy or targeted therapy
Study NCT04881591 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment as usual + APP
Description: Participants at this condition will receive the usual medical treatment for their scoliosis but also they will be monitored daily using the Scoliosis Pain Monitor APP. Alarms will be generated in the face of certain preestablished undesired events. Physicians will be asked to call patients and change/stop treatment if an alarm is received.
Study NCT06174519 — intervention group
Intervention type: DEVICE
Intervention: Medical device simulation
Description: For the subjects included, investigators used the iAST® tool to predict which antibiotics would have been recommended as the top three choices both for empiric and semi-targeted therapy and recorded this data with the percentage of coverage predicted (the first three antibiotics in the iAST® ranking that have been tested in the antibiogram of the center where the study was carried were chosen). Investigators checked the final microbiological reports and logged if the recovered bacteria were susceptible to the drug prescribed by doctors and simulated by the iAST® tool according to the final antibiogram results.
Study NCT05033015 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mouth rinse
Description: To test a novel mouth rinse containing enzymes to prevent development of WSL with a control